Cargando…

Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial

Annual influenza vaccination is recommended, but its efficacy in dialysis population is still controversial. Here we aimed to compare the dynamic changes of immune response between various influenza vaccination protocols in hemodialysis patients. A 18-week open label, non-randomized, controlled tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Yu-Tzu, Wang, Jen-Ren, Lin, Meng-Te, Wu, Chi-Jung, Tsai, Ming-Song, Wen-Chi, Chiang Lin, Shih, Te-En, Kuo, Te-Hui, Song, Eing-Ju, Sung, Junne-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751607/
https://www.ncbi.nlm.nih.gov/pubmed/26869526
http://dx.doi.org/10.1038/srep20725
_version_ 1782415614102470656
author Chang, Yu-Tzu
Wang, Jen-Ren
Lin, Meng-Te
Wu, Chi-Jung
Tsai, Ming-Song
Wen-Chi, Chiang Lin
Shih, Te-En
Kuo, Te-Hui
Song, Eing-Ju
Sung, Junne-Ming
author_facet Chang, Yu-Tzu
Wang, Jen-Ren
Lin, Meng-Te
Wu, Chi-Jung
Tsai, Ming-Song
Wen-Chi, Chiang Lin
Shih, Te-En
Kuo, Te-Hui
Song, Eing-Ju
Sung, Junne-Ming
author_sort Chang, Yu-Tzu
collection PubMed
description Annual influenza vaccination is recommended, but its efficacy in dialysis population is still controversial. Here we aimed to compare the dynamic changes of immune response between various influenza vaccination protocols in hemodialysis patients. A 18-week open label, non-randomized, controlled trial was conducted during 2011–2012. The efficacy between unvaccinated, one- and two-dose regimens were evaluated in 175 hemodialysis patients. Immunogenic profiles were assessed by hemagglutination-inhibition assays. At 3–9 weeks post-vaccination, antibody responses were similar between the one- and two-dose regimens, while the seroprotection rates (antibody titer ≥1:40) for influenza A were 55.6–82.5% in the adult (18–60 years) and 33.3–66.7% in the elderly (>60 years). Meanwhile, the seroprotection rates for influenza B were low (4.0–25.0%). By 18 weeks post-vaccination, the seroprotection rates for influenza A and B declined (0.0–33.3%) in both the adult and elderly receiving one- or two-dose regimens. Of dialysis patients, at most 2.4% developed moderate to severe adverse effects(myalgia and headache) after vaccination. In conclusion, the two-dose regimen could not improve immune responses than the one-dose regimen in hemodialysis patients; meanwhile the induced protective antibodies of both regimens could not be maintained for more than 4 months. Modification of current influenza vaccination strategy in dialysis population should be re-considered.
format Online
Article
Text
id pubmed-4751607
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47516072016-02-22 Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial Chang, Yu-Tzu Wang, Jen-Ren Lin, Meng-Te Wu, Chi-Jung Tsai, Ming-Song Wen-Chi, Chiang Lin Shih, Te-En Kuo, Te-Hui Song, Eing-Ju Sung, Junne-Ming Sci Rep Article Annual influenza vaccination is recommended, but its efficacy in dialysis population is still controversial. Here we aimed to compare the dynamic changes of immune response between various influenza vaccination protocols in hemodialysis patients. A 18-week open label, non-randomized, controlled trial was conducted during 2011–2012. The efficacy between unvaccinated, one- and two-dose regimens were evaluated in 175 hemodialysis patients. Immunogenic profiles were assessed by hemagglutination-inhibition assays. At 3–9 weeks post-vaccination, antibody responses were similar between the one- and two-dose regimens, while the seroprotection rates (antibody titer ≥1:40) for influenza A were 55.6–82.5% in the adult (18–60 years) and 33.3–66.7% in the elderly (>60 years). Meanwhile, the seroprotection rates for influenza B were low (4.0–25.0%). By 18 weeks post-vaccination, the seroprotection rates for influenza A and B declined (0.0–33.3%) in both the adult and elderly receiving one- or two-dose regimens. Of dialysis patients, at most 2.4% developed moderate to severe adverse effects(myalgia and headache) after vaccination. In conclusion, the two-dose regimen could not improve immune responses than the one-dose regimen in hemodialysis patients; meanwhile the induced protective antibodies of both regimens could not be maintained for more than 4 months. Modification of current influenza vaccination strategy in dialysis population should be re-considered. Nature Publishing Group 2016-02-12 /pmc/articles/PMC4751607/ /pubmed/26869526 http://dx.doi.org/10.1038/srep20725 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Chang, Yu-Tzu
Wang, Jen-Ren
Lin, Meng-Te
Wu, Chi-Jung
Tsai, Ming-Song
Wen-Chi, Chiang Lin
Shih, Te-En
Kuo, Te-Hui
Song, Eing-Ju
Sung, Junne-Ming
Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial
title Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial
title_full Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial
title_fullStr Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial
title_full_unstemmed Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial
title_short Changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial
title_sort changes of immunogenic profiles between a single dose and one booster influenza vaccination in hemodialysis patients – an 18-week, open-label trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751607/
https://www.ncbi.nlm.nih.gov/pubmed/26869526
http://dx.doi.org/10.1038/srep20725
work_keys_str_mv AT changyutzu changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial
AT wangjenren changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial
AT linmengte changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial
AT wuchijung changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial
AT tsaimingsong changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial
AT wenchichianglin changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial
AT shihteen changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial
AT kuotehui changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial
AT songeingju changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial
AT sungjunneming changesofimmunogenicprofilesbetweenasingledoseandoneboosterinfluenzavaccinationinhemodialysispatientsan18weekopenlabeltrial